Dallas-based BioLum Sciences, a medical device startup for asthma, has closed another investment round from Intelis Capital, an early-stage venture capital firm that’s also based in Dallas. BioLum Sciences declined to disclose the round’s amount.
According to BioLum Sciences, the investment will help “finalize product development, prepare for clinical trials, and accelerate commercialization.” Currently, the company is conducting clinical research to finalize its technology before trials are expected to start early next year.
The company’s device allows asthmatics to monitor their illness, personalize treatment plans, and reduce costly asthmatic episodes. Patients scan their breath with BioLum Science’s device; doctors can then view the results to determine patient lung function and efficient treatment plans.
Edward Allegra, co-founder and CEO of BioLum Sciences, said in a statement: “We have one ultimate goal for the rest of the year: to have a commercially viable device ready for clinical trials by 2018. The next few months look very exciting for us as we continue executing our vision and mission.”